Institutional members access full text with Ovid®

Share this article on:

Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection

Martin, Genevieve E.; Gossez, Morgane; Williams, James P.; Stöhr, Wolfgang; Meyerowitz, Jodi; Leitman, Ellen M.; Goulder, Philip; Porter, Kholoud; Fidler, Sarah; Frater, John; and the SPARTAC Trial Investigators

doi: 10.1097/QAD.0000000000001382
Basic Science: Concise Communication

Objective(s): An HIV cure will impose aviraemia that is sustained following the withdrawal of antiretroviral therapy (ART). Understanding the efficacy of novel interventions aimed at curing HIV requires characterization of both natural viral control and the effect of ART on viral control after treatment interruption.

Design: Analysis of transient viral control in recent seroconverters in the Short Pulse AntiRetroviral Therapy at Acute Seroconversion trial.

Methods: We compared untreated and treated HIV seroconverters (n = 292) and identified periods of control (plasma HIV RNA < 400 copies/ml for ≥16 weeks off therapy) in 7.9% of ART-naive participants, and in 12.0% overall. HIV DNA was measured by qPCR, and HIV-specific CD8+ responses were measured by enzyme-linked immunosorbent spot assay (ELISpot). T-cell activation and exhaustion were measured by flow cytometry.

Results: At baseline, future controllers had lower HIV DNA, lower plasma HIV RNA, higher CD4+ : CD8+ ratios (all P < 0.001) and higher CD4+ cell counts (P < 0.05) than noncontrollers. Among controllers, the only difference between the untreated and those who received ART was higher baseline HIV RNA in the latter (P = 0.003), supporting an added ART effect.

Conclusion: Consideration of spontaneous remission in untreated individuals will be critical to avoid overestimating the effect size of new interventions used in HIV cure studies.

aNuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford

bMRC Clinical Trials Unit at University College London, London

cDepartment of Paediatrics, University of Oxford, Oxford, UK

dHarvard Medical School, Boston, Massachusetts, USA

eHIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa

fResearch Department of Infection and Population Health, University College London

gDivision of Medicine, Wright Fleming Institute, Imperial College, London

hThe Oxford Martin School

iOxford National Institute of Health Research Biomedical Research Centre, Oxford, UK.

Correspondence to John Frater, Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford OX1 3SY, UK. E-mail:

Received 23 September, 2016

Revised 9 November, 2016

Accepted 30 November, 2016

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2017 Wolters Kluwer Health, Inc.